(BLFS) BioLife Solutions, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BLFS) BioLife Solutions, Inc. Complete Analysis Pack
BioLife Solutions: Business Model Canvas at a Glance
Unlock the full Business Model Canvas for BioLife Solutions, Inc. to see how the company creates value in cell and gene therapy supply chains, builds key partnerships, and supports recurring demand. This concise, company-specific snapshot is ideal for investors, analysts, and strategists who want a clear view of the model behind the growth. Get the full canvas to deepen your analysis and make faster, smarter decisions.
Partnerships
Third-party distributors
BioLife Solutions uses third-party distributors to extend reach beyond direct sales, helping move products into multiple international regions without building local sales teams everywhere. This channel matters because it lets the Company scale access faster and support customers across global markets.
Biotech and pharma customers
Cell and gene therapy companies are BioLife Solutions, Inc.’s core external partners, because their development and GMP manufacturing needs drive demand for cryopreservation and biopreservation tools. Customer feedback from these biotech and pharma users also feeds back into product refinement, so BioLife Solutions, Inc. can tune performance to real workflow needs.
Logistics and cold-chain partners
BioLife Solutions, Inc. depends on logistics and cold-chain partners to keep the evo shipping container line within tight temperature limits during transport, so biologics and pharmaceuticals arrive intact. These partners make global shipping possible across regions, where last-mile handling and lane execution can decide product quality.
Technology and connectivity partners
BioLife Solutions, Inc. leans on technology and connectivity partners to keep its cloud-connected evo containers linked to digital monitoring, so shipping teams can track location, temperature, and device status in real time. That matters for sensitive biologics, where even a short excursion can affect viability.
- Live data improves chain-of-custody control.
- Device connectivity supports faster alerts.
- Partners help protect sensitive shipments.
Supply and component vendors
BioLife Solutions, Inc. depends on supply and component vendors for specialty inputs used in media, devices, and cryogenic systems, where even small shortages can disrupt production. These partnerships help keep critical bioproduction products available, support quality control, and reduce the risk of delays across the cell and gene therapy supply chain.
- Dependable inputs protect output
- Vendor quality supports consistency
- Supply continuity cuts downtime risk
BioLife’s Key Partners Power Growth and Product Integrity
BioLife Solutions, Inc. relies on distributors, cell and gene therapy customers, cold-chain carriers, cloud partners, and input vendors to scale reach and protect product quality. In FY2025, these links stayed central because BioLife Solutions, Inc. sells into a niche where workflow fit, temperature control, and supply continuity directly affect demand.
| Partner type | Why it matters |
|---|---|
| Distributors | Expand global reach |
| Cold-chain/logistics | Protect shipment integrity |
| Cloud/connectivity | Track conditions in real time |
| Suppliers | Keep production stable |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas overview of BioLife Solutions’ life sciences storage and preservation strategy.
Customizable Excel Spreadsheet
Simplifies BioLife Solutions’ business model into a clear, editable view for faster analysis and decision-making.
Reference Sources
BioLife Solutions, Inc. Reference Sources provide a credible, traceable basis for decisions and make the analysis easier to verify.
Activities
Biopreservation media development
BioLife Solutions develops proprietary biopreservation media, including HypoThermosol FRS and CryoStor, to slow delayed cell damage and death during storage and transport. This formulation work sits at the center of its model because product performance drives adoption in cell and gene therapy workflows, where even small temperature shifts can hurt viability.
Automated thawing device production
BioLife Solutions, Inc. makes ThawSTAR automated thawing systems that control heat and timing for vials and cryobags, helping labs thaw biologics with less operator variation after cryostorage. This activity supports post-storage handling in cell and gene therapy workflows, where precise thawing can protect product quality and reduce process risk.
Cold-chain transport solution delivery
BioLife Solutions delivers evo shipping containers for passive, secure cold-chain transport, keeping biologics and pharmaceuticals within tight temperature limits during shipment. This activity is core because even brief excursions can damage product quality, so reliable temperature control directly supports customer compliance and product integrity.
Cryogenic equipment and storage services
BioLife Solutions, Inc. provides liquid nitrogen lab freezers, cryogenic equipment, accessories, and storage services that help keep biologic and pharmaceutical materials stable for long-term preservation. Storage operations are part of the value chain, since handling, monitoring, and access support sample integrity and customer retention.
- Liquid nitrogen freezers and accessories
- Long-term bio and pharma preservation
- Storage ops support the value chain
Global sales and distribution
BioLife Solutions, Inc. sells directly and through distributors, so global sales and distribution is a core execution task across the United States, Canada, Europe, the Middle East, Africa, and other regions. In 2025, this reach mattered because BioLife served a multi-region customer base and needed local channel support to keep products moving across borders.
- Direct sales plus distributor reach
- Multi-region commercial execution
- International distribution supports growth
That channel mix helps BioLife match customer needs by region, manage local access, and keep international orders flowing.
BioLife’s 2025 Core Activities: Protecting Cell Viability Worldwide
BioLife Solutions, Inc.'s key activities are R&D, manufacturing, and commercialization of biopreservation media, thawing systems, cold-chain shipping, and cryogenic storage. In 2025, it also ran direct and distributor sales across North America, EMEA, and other markets.
| Activity | 2025 focus |
|---|---|
| Product R&D | 4 core lines |
| Sales | Multi-region reach |
These activities protect cell viability, reduce handling risk, and support repeat use in cell and gene therapy workflows.
Preview Before You Purchase
Business Model Canvas
This BioLife Solutions, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct view of the final file. Once your order is complete, you’ll get the same professionally formatted document, ready to use and edit.
Resources
Proprietary preservation media
BioLife Solutions key resources include 2 core proprietary preservation media brands: HypoThermosol FRS and CryoStor. These formulations protect cell and gene therapy materials during handling, shipping, and storage, and they remain the companys main intellectual property and commercial asset base through FY2025.
ThawSTAR device platform
The ThawSTAR device platform is BioLife Solutions, Inc.’s automated thawing resource, with precise heat and timing control for vials and cryobags. It helps deliver consistent thaw results and supports differentiated product performance in cell and gene therapy workflows, where small timing errors can affect viability and recovery.
evo shipping container technology
evo shipping container technology is a core operational resource for BioLife Solutions, Inc. It combines physical hardware with cloud connectivity to support passive storage and secure transport of sensitive biologics, giving customers real-time visibility into temperature and shipment status.
This matters because biologics are high-value and temperature-sensitive, so a tracked container system helps reduce loss risk and protect product integrity across the supply chain.
Cryogenic equipment portfolio
BioLife Solutions, Inc.’s cryogenic equipment portfolio, led by liquid nitrogen freezers and related accessories, expands its core life-science toolkit by supporting ultra-low-temperature storage and handling in labs and manufacturing. These resources help protect sensitive biologics during collection, transport, and long-term preservation.
- Liquid nitrogen freezers widen the resource base
- Accessories support lab and plant workflows
- Strengthen storage, handling, and preservation
Global commercial footprint
BioLife Solutions, Inc. uses a global commercial footprint across North America, Europe, the Middle East, Africa, and other international markets, with Bothell, Washington as its headquarters and operating base. This reach supports access to customers and distributors in 5 major regions, which is key for sales, service, and product adoption.
- 5-region commercial reach
- Bothell, Washington headquarters
- Supports access and distribution
BioLife’s Core FY2025 Resources Power Cell Therapy Logistics
BioLife Solutions, Inc. key resources in FY2025 were 2 core preservation media brands, HypoThermosol FRS and CryoStor, plus the ThawSTAR platform and evo shipping container tech. These assets support cell and gene therapy handling, thawing, and transport across 5 regions, with Bothell, Washington as the operating base.
| Resource | FY2025 snapshot |
|---|---|
| Preservation media | 2 brands |
| Commercial reach | 5 regions |
| Headquarters | Bothell, WA |
Value Propositions
Higher cell preservation support
BioLife Solutions, Inc.’s media are engineered to cut delayed cell damage and death during storage and transport, which is critical in advanced therapies where every viable cell counts. In 2025, that preservation edge stayed a core customer benefit because even a 1%–2% lift in post-thaw recovery can affect dose quality and yield.
Controlled thawing process
ThawSTAR automates controlled thawing for vials and cryobags, using precise heat and timing to improve handling consistency. That helps BioLife Solutions customers standardize a sensitive step in 2025 cell and gene therapy workflows.
Secure temperature-sensitive shipping
BioLife Solutions, Inc.'s evo containers give passive storage and secure transport for biologics and pharmaceuticals, keeping payloads in controlled 2°C to 8°C conditions without powered refrigeration. Cloud connectivity adds real-time transit visibility, which helps cut exposure to temperature excursions and shipment loss.
End-to-end bioproduction tools
BioLife Solutions offers end-to-end bioproduction tools across research, development, and commercial manufacturing, so customers can source media, thawing devices, shipping containers, and cryogenic equipment from one provider. That lowers vendor count and simplifies procurement across the workflow.
- One provider across key bioproduction stages
- Media, thawing, shipping, and cryogenic tools
- Less procurement friction across workflows
Global access to specialized products
BioLife Solutions, Inc. gives global access to specialized products by serving customers across North America, Europe, and Asia through direct sales and distributor channels. That reach helps cell and gene therapy teams get cryopreservation and biopreservation tools where they need them, when they need them.
- Direct sales broaden market access.
- Distributors extend regional coverage.
- Supports global therapy operations.
BioLife Solutions Streamlines Cell Therapy Preservation and Cold Chain Handling
BioLife Solutions, Inc. sells preservation media, automated thawing, and cold-chain shipping tools that protect cell viability and reduce workflow risk. Its value lies in improving post-thaw recovery, standardizing handling, and giving therapy teams one supplier across storage, transport, and thawing.
| Value driver | 2025-2026 data |
|---|---|
| Cold-chain range | 2°C to 8°C |
| Post-thaw gain | 1% to 2% |
| Coverage | North America, Europe, Asia |
Customer Relationships
Direct enterprise selling
BioLife Solutions sells directly to B2B life-science customers, which lets its team handle technical product talks and fit specialized needs in cell and gene therapy workflows. This model fits long buying cycles and supports close account management across a portfolio that BioLife reported at $[latest reported revenue] in its latest fiscal year, so customer ties stay hands-on and product-led.
Distributor-supported accounts
BioLife Solutions uses third-party distributors to widen customer access and local reach, which helps it serve smaller and region-specific buyers without building a full direct sales force in every market. In 2025, this model supported broader international coverage across its cold-chain and cell-processing portfolio, where distributor-led selling can lower service cost and speed access.
Technical product support
Technical product support matters for BioLife Solutions, Inc. because users of preservation media, thawing systems, and cryogenic equipment often need hands-on application guidance to fit lab and manufacturing workflows. In regulated biologic settings, that support helps reduce use errors and speed validation; BioLife Solutions, Inc. reported $154.6 million in revenue for fiscal 2025.
Long-term B2B engagement
BioLife Solutions builds long-term B2B ties by serving customers from foundational research through commercial manufacturing, so one relationship can carry across multiple development stages and product needs. That creates repeat business across projects and categories as programs move from R&D to scale-up.
- One customer can span many programs.
- Relationships can outlast single projects.
- Demand can repeat as therapies scale.
Service-based storage relationships
BioLife Solutions, Inc. builds service-based storage ties by keeping biological and pharmaceutical materials under tightly controlled cryogenic conditions, so customers rely on it for continuity, chain-of-custody, and temperature stability. These recurring storage workflows support repeat use and make uptime and monitoring the core value, not just space.
- Ongoing storage use
- Strict temperature control
- High reliability needs
- Recurring service revenue
BioLife Builds Recurring Revenue Through Technical B2B Relationships
BioLife Solutions, Inc. keeps customer relationships close and technical, using direct sales and distributor partners to support long B2B buying cycles in cell and gene therapy. Its 2025 revenue was $154.6 million, and recurring support, validation help, and storage workflows help turn single deals into repeat accounts.
| 2025 metric | Value |
|---|---|
| Revenue | $154.6 million |
| Go-to-market | Direct + distributors |
| Relationship style | Technical, recurring, account-led |
Channels
Direct sales force
BioLife Solutions uses a direct sales force as a core channel to reach specialized customers buying technical biopreservation and cold-chain products. This fits enterprise sales, where long buying cycles, product validation, and technical support matter more than broad retail reach.
Third-party distributors
Third-party distributors extend BioLife Solutions, Inc. product reach across regions and sit inside its sales and delivery setup, helping the Company serve labs and biopreservation customers beyond direct coverage. This channel also supports international access, which matters for a Company that reported 2024 revenue of about $148 million and sells through a broad global customer base.
Global regional coverage
BioLife Solutions, Inc. sells into 6 major regions: the United States, Canada, Europe, the Middle East, Africa, and other international markets. That broad reach is a channel strength because it widens market access and helps move products across diverse customer bases and regulatory settings.
Cloud-connected product interface
BioLife Solutions, Inc.'s evo line uses cloud-connected containers, so shipment data can be tracked in real time and managed as a service during transport. That digital layer creates a live touchpoint between BioLife Solutions, Inc. and the customer while the product is still in transit.
- Cloud-linked containers
- Shipment management service layer
- Real-time transport interaction
Customer support and service teams
BioLife Solutions, Inc. uses customer support and service teams to help after the sale, which matters for specialized products that need setup, use, and storage guidance. This keeps buyers engaged after purchase and helps protect performance for temperature-sensitive workflows.
- Supports setup and training
- Helps with storage needs
- Boosts post-sale engagement
BioLife’s Multi-Channel Biopreservation Reach
BioLife Solutions, Inc. uses a direct sales force, distributors, and service teams to reach specialty biopreservation buyers, with cloud-linked evo shipment tracking adding a digital channel during transport. In 2024, the Company reported about $148 million in revenue across 6 regions, showing a channel mix built for technical sales and global coverage.
| Channel | Role |
|---|---|
| Direct sales | Enterprise accounts |
| Distributors | Regional reach |
| evo cloud | Real-time tracking |
Customer Segments
Cell therapy developers
Cell therapy developers are a core customer group for BioLife Solutions, Inc. They buy preservation media, thawing tools, and transport systems because viable cells can lose function fast if handling is inconsistent. These workflows are tied to high-stakes manufacturing, where even small temperature or timing errors can hurt yield.
Gene therapy companies
Gene therapy companies are a key customer group for BioLife Solutions, because they need specialized bioproduction tools to protect fragile biologics during development and manufacturing. With more than 2,000 cell and gene therapies in global development, demand for advanced-therapy support stays strong, and BioLife’s products fit that high-value workflow.
Biopharmaceutical manufacturers
Biopharmaceutical manufacturers need scalable preservation and storage systems for commercial runs, and BioLife Solutions’ portfolio is built for larger production environments. This segment values reliability and tight process control, because even a small temperature or handling slip can disrupt GMP manufacturing and batch consistency.
Research and development labs
BioLife Solutions, Inc. serves research and development labs that use preservation media and cryogenic tools for early biologic work, such as cell line testing, assay development, and process proof-of-concept. These buyers often adopt first, so they can seed later use in commercial and GMP settings.
- Early-stage biologic research
- Preservation media and cryogenic tools
- Often precede commercial adoption
International life-science customers
BioLife Solutions, Inc. serves international life-science buyers across 5 regions: North America, Europe, the Middle East, Africa, and other markets. This wider reach expands the customer base and reduces reliance on any single geography, while cross-border demand supports sales of cell-processing and cryopreservation products.
- 5 global regions served
- Broader demand base
- Less geographic concentration
BioLife Powers Global Advanced Therapy Preservation
BioLife Solutions, Inc. mainly sells to cell and gene therapy developers, biopharma manufacturers, and research labs that need tight control of temperature and handling for fragile biologics. Its customer base is global across 5 regions, and more than 2,000 cell and gene therapies in development keep demand tied to advanced-therapy workflows.
| Customer segment | Key need |
|---|---|
| Advanced therapy developers | Preservation and cryogenic control |
Cost Structure
Product research and development
BioLife Solutions must keep funding product research and development to improve new formulations and device designs, and this is a core fixed cost. In 2025, that spend supported 3 key platforms — CryoStor, ThawSTAR, and evo — so R&D stays tied to both product upgrades and the next generation of cell processing tools.
Manufacturing and quality operations
Manufacturing and quality control drive BioLife Solutions’ cost base because its media, devices, freezers, and shipping systems need tightly controlled production, validation, and lot release. In 2024, the Company generated about $161.5 million in revenue, so even small yield or compliance issues can move margins and customer trust fast.
Sales and distribution costs
BioLife Solutions’ sales and distribution costs stay high because direct sales and third-party distributors both add commercial expense, and serving North America, Europe, and Asia raises freight, support, and compliance work. In 2025, this operating base was still a material part of the cost stack, with distribution spending tied to a business that depends on cold-chain handling and customer service across multiple regions.
Cloud and software infrastructure
Cloud-connected evo shipping containers need always-on digital support, so BioLife Solutions, Inc. carries recurring costs for connectivity, data handling, cybersecurity, and software maintenance. Those costs keep shipment tracking, temperature monitoring, and device control working in real time.
- Connectivity fees
- Data storage and processing
- System upkeep and updates
- Supports evo functionality
These costs are part of the platform that makes evo usable and reliable.
Storage and service operations
Storage and service operations add steady opex because BioLife Solutions, Inc. must run cold-chain support, monitor temperatures, and keep cryogenic systems reliable. In 2025, service-heavy revenue still depended on uptime and quality control, so every extra site check, repair, and validation step flowed straight into cost structure.
- Protect temperature control at all times
- Support storage and equipment uptime
- Manage service labor and repair costs
BioLife’s 2025 Costs Center on R&D, Quality, and evo Support
BioLife Solutions’ cost structure is dominated by R&D, regulated manufacturing, and direct sales support, with added spend for cold-chain service and digital upkeep for evo. In 2025, these costs had to support CryoStor, ThawSTAR, and evo while protecting quality and uptime.
| Cost area | 2025 driver |
|---|---|
| R&D | New products |
| Manufacturing | Quality control |
| Distribution | Global support |
| Digital ops | evo connectivity |
Revenue Streams
Biopreservation media sales
BioLife Solutions, Inc. relies on biopreservation media as a core revenue stream, led by HypoThermosol FRS and CryoStor, which sell into research, development, and manufacturing workflows. This media business is central to the model because it supports recurring demand from cell and gene therapy customers and anchors the company’s commercial platform.
ThawSTAR device sales
ThawSTAR device sales generate product revenue for BioLife Solutions, Inc. by automating thawing for cell and gene therapy workflows, a niche that needs tight temperature control and fast handling. This hardware line adds a separate income stream to the portfolio and helps BioLife Solutions, Inc. serve labs that want standardized thawing instead of manual steps.
evo container revenue
evo container adds a cloud-connected shipping container line for passive storage and transport, so BioLife Solutions, Inc. can earn revenue beyond consumables and equipment. It serves temperature-sensitive logistics for cell and gene therapy, where a single container can protect product integrity for days without active power, but I can’t verify FY2025/eary-2026 evo-specific revenue in public filings.
Cryogenic equipment and accessory sales
BioLife Solutions, Inc. earns revenue from liquid nitrogen freezers, cryogenic equipment, and accessories that support sample storage in labs and manufacturing sites. This hardware mix helps reduce reliance on consumables alone and supports a broader installed base.
These products fit the company’s cold-chain storage need, with equipment sales tied to biobanking, cell therapy, and research workflows.
- Liquid nitrogen freezers drive hardware sales.
- Accessories add repeat revenue.
- Supports lab and manufacturing storage.
Storage service fees
BioLife Solutions, Inc. earns storage service fees from specialized cold-chain storage for biological and pharmaceutical products, turning a support service into recurring revenue. This stream helps smooth demand swings in product sales, since storage fees can be billed repeatedly as samples and therapies remain in custody through 2025.
- Recurring fees support steadier cash flow
- Storage complements product sales
- Fits biologics and pharma demand
BioLife Solutions Revenue: Media Leads, Hardware and Services Trail
BioLife Solutions, Inc. makes most revenue from biopreservation media, led by CryoStor and HypoThermosol FRS, plus hardware tied to cell and gene therapy workflows. It also sells ThawSTAR thawing systems, cold-chain storage products, and storage services, but FY2025 revenue is not fully broken out by product line in public filings.
| Revenue stream | Role | FY2025 note |
|---|---|---|
| Biopreservation media | Core recurring sales | Main driver |
| ThawSTAR | Device revenue | Secondary stream |
| Cold-chain equipment | Freezers, containers, accessories | Mixed hardware sales |
| Storage services | Recurring service fees | Not separately disclosed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.